BOK and breast carcinoma: Next, we tested whether BOK is indeed a bonafide target of miR-296-5p by assessing BOK levels in MDA-MB-231 and MDA-MB-468 breast cancer cells, ectopically expressing miR-296-5p or anti-miR-296-5p (miR-296-5p inhibitor).